Biotechnology company Bright Minds has been using psychedelic compounds, such as LSD and psilocybin, in order to treat clinical depression. Earlier in one of their seminars, the team at Bright minds was able to show an association between these compounds and lower rates of depression in patients and have conducted many experiments where they were able to treat depression with these psychedelics to the most extent. Now, their goal is to see if these compounds can be used as tools in discovering more effective ways to help those already suffering other various mental conditions.

1) How It Works

Psychedelic drugs are an intriguing area of scientific study these days. Many pharma and bio companies are now venturing into this field and developing effective medicines for mental problems using various psychedelics drugs. For example, the Food and Drug Administration is currently reviewing a breakthrough therapy designation for psilocybin (AKA magic mushrooms), so it seems that biotechnology companies will soon be able to develop psychedelic-based treatments for depression formally. In addition, several studies already exist on how psychedelics have helped treat anxiety and post-traumatic stress disorder in patients.

2) What They're Looking At

The biotech company, called Bright Minds Bio, wants to create new treatments for depression and other mental disorders using psychedelics. They focus on psilocybin, a chemical that occurs naturally in psychedelic mushrooms; MDMA, or ecstasy; and LSD. They are currently running a trial in phase two of three clinical trials meant to test these drugs as potential therapeutic aids for patients with treatment-resistant depression.

3) Concerns About Psychedelics In Therapy

Although some scientists and therapists believe that psychedelics could be an incredibly effective treatment for people suffering from depression, many others are concerned about their safety. There's a range of psychedelic drugs — including LSD, DMT, psilocybin, ayahuasca and MDMA — each with its effects. While most research into psychedelics is done on adults, some experts wonder whether using these drugs in younger people might cause lasting damage. Also raising eyebrows: Some studies suggest that older patients with depression might be more likely to suffer serious side effects from psychedelics than younger patients — though there's no clear consensus on why that might be.

Bright Minds Bio's Approach

At Bright Minds Bio, our team of neuroscientists is dedicated to developing the next generation of serotonin medicines. These medicines will specifically target specific diseases, which will further result in a substantial reduction in side effects and enhanced therapeutic efficacy, ultimately changing patients' lives. For example, current medicines for treating anxiety, depression, seizures, and other mental illnesses have severe side effects, and patients have a limited response to therapy and treatment. So, we've developed better compounds that improve the existing state of the art, such as those that target particular serotonin receptors in the brain and improve safety and efficacy.

Visit our website for more information on biotechnology company.